Hansa Biopharma beruft Shannon Campbell und Gregory Perry in Verwaltungsrat, Bologna tritt zurück

Von Public Technologies05:00 (UTC), 24 September 2026 Aktualisiert

Hansa Biopharma wählte Shannon Campbell und Gregory Perry per 22. September 2026 in den Verwaltungsrat.
Campbell war Executive Vice President und Chief Commercial Officer bei Merus; zuvor leitende kommerzielle Funktionen bei Novartis und Bayer.
Perry war Chief Financial Officer bei Merus; zuvor CFO von Finch Therapeutics, Novelion Therapeutics und ImmunoGen.
Michael Bologna, Chief Investment Officer bei NovaQuest Capital Management, scheidet aus dem Verwaltungsrat aus.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansa Biopharma AB published the original content used to generate this news brief via Cision (Ref. ID: 20260923:BIT:4495:0) on September 24, 2026, and is solely responsible for the information contained therein.